WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca is investing $300 million in a state-of-the-art facility in Rockville, MD to launch its life-saving cell therapy platforms in the US for critical cancer trials and future commercial supply. More than 150 new highly skilled jobs will be created to initially focus on manufacturing T-cell therapies to enable clinical trials to be conducted around the world. Over time, the site may expand its focus to support other disease areas. The site represents the latest inv ...

Artificial intelligence grabbed most of the headlines last year, but weight loss stocks were equally noteworthy. It grew slowly for several years but really went stratospheric last year.The wider availability of Ozempic and Wegovy set the world on fire. A class of drugs known as glycogen-like peptide-1 (GLP-1) therapies for diabetes and obesity, demand was fueled by celebrities and social media influencers touting their slimming effects. They also spurred further investment into weight-loss-in-a-pill becaus ...

AstraZeneca PLC (LSE:AZN) shares have continued their underperformance from the final quarter of last year into January, with Barclays identifying three major debates around the stock ahead of this week's results.  Since hitting an all-time high above £128 per share last April, the shares have fallen more than 19% and in the fourth quarter underperformed the Stoxx Europe 600 health sector by around 6%. The bank noted that this was "due to concerns about next year's numbers being too high", which is a trade ...

In its upcoming report, Astrazeneca (AZN) is predicted by Wall Street analysts to post quarterly earnings of $0.76 per share, reflecting an increase of 10.1% compared to the same period last year. Revenues are forecasted to be $12.11 billion, representing a year-over-year increase of 8%.The consensus EPS estimate for the quarter has been revised 1.9% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates durin ...

AstraZeneca (AZN) will report fourth-quarter and full-year 2023 results on Feb 8, before market open. In the last reported quarter, the company beat earnings expectations by 8.75%.Factors to NoteSales of AstraZeneca’s key medicines, mainly cancer drugs — Lynparza, Tagrisso, and Imfinzi — and diabetes medicine Farxiga, are expected to have driven the company’s top line in the fourth quarter, backed by strong demand trends.Approvals for new indications have been boosting sales growth of some key drugs like Im ...

Volatility has been the name of the game on Wall Street since this decade began. In successive years, we've watched the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite trade off bear and bull markets.Although the ageless Dow and benchmark S&P 500 have galloped to fresh record highs, the growth-focused Nasdaq Composite has yet to take out its previous peak, which was set in November 2021. Whereas some traders may view this as disappointing, long-term investors are liable to see this as an opportu ...

AstraZeneca (AZN) announced that the FDA has granted priority review to a supplemental biologics license application (sBLA) seeking approval for the expanded use of Enhertu (trastuzumab deruxtecan) to treat unresectable or metastatic HER2-positive solid tumors in heavily-pretreated patients. A filing designated as a priority review reduces the review period by four months. A final decision is expected during the second quarter of 2024.Enhertu, a specifically engineered HER2-directed antibody-drug conjugate ...

We expect GSK plc. (GSK) to beat expectations when it reports fourth-quarter and full-year 2023 results on Jan 31. In the last reported quarter, the company delivered an earnings surprise of 15.60%.Factors to NoteGSK reports financial figures under three segments — Specialty Medicines, Vaccines and General Medicines.In the fourth quarter, higher sales of newer products like Arexvy, Cabenuva, Dovato, Trelegy Ellipta and Shingrix are likely to have offset the decline in sales of older HIV drugs and respirator ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment or who have no satisfactory alternative treatment options. The sBLA is based on data from the ongoing DESTINY-PanTumor02 Phase II ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment or who have no satisfactory alternative treatment options. ENHERTU is a specifical ...